We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+9.06%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.6B
AUM Growth
+$2.6B
(+22%)
Cap. Flow
+$859M
Cap. Flow
% of AUM
5.88%
Top 10 Holdings %
Top 10 Hldgs %
21.92%
Holding
958
New
131
Increased
364
Reduced
334
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$135M |
| 2 |
Royal Bank of Canada
RY
|
+$120M |
| 3 |
Agilent Technologies
A
|
+$72.5M |
| 4 |
UnitedHealth
UNH
|
+$71.5M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$64.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$90.3M |
| 2 |
Amgen
AMGN
|
+$88.7M |
| 3 |
Allstate
ALL
|
+$52.2M |
| 4 |
Union Pacific
UNP
|
+$47.1M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$44.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.42% |
| 2 | Technology | 23.2% |
| 3 | Consumer Discretionary | 9.14% |
| 4 | Financials | 8.63% |
| 5 | Communication Services | 7.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$4.9B
| $23.4M | 0.16% |
417,471
+170,869
| +69% | +$8.88M |
|
152
ExxonMobil
XOM
$651B
| $23.4M | 0.16% |
371,097
+36,577
| +11% | +$2.18M |
|
153
BioNTech
BNTX
$22.6B
| $23.3M | 0.16% |
104,097
+16,336
| +19% | +$3.08M |
|
154
Ameresco
AMRC
$1.15B
| $23.1M | 0.16% |
367,506
+118,504
| +48% | +$6.38M |
|
155
Otis Worldwide
OTIS
$27.4B
| $23M | 0.16% |
281,838
+203,163
| +258% | +$15.6M |
|
156
Netflix
NFLX
$292B
| $22.9M | 0.16% |
433,460
-12,310
| -3% | -$629K |
|
|
NUAN
157
DELISTED
Nuance Communications, Inc.
NUAN
| $22.8M | 0.16% |
418,618
+336,468
| +410% | +$17.7M |
|
158
Sherwin-Williams
SHW
$78.3B
| $22.8M | 0.16% |
83,599
+29,638
| +55% | +$8.12M |
|
|
GRA
159
DELISTED
W.R. Grace & Co.
GRA
| $22.5M | 0.15% |
325,773
+285,584
| +711% | +$19.2M |
|
160
Power Integrations
POWI
$3.54B
| $22.5M | 0.15% |
273,787
+69,852
| +34% | +$5.64M |
|
161
Parker-Hannifin
PH
$125B
| $22.3M | 0.15% |
72,603
+18,191
| +33% | +$5.63M |
|
162
Ionis Pharmaceuticals
IONS
$9.35B
| $22M | 0.15% |
552,566
+305,612
| +124% | +$12M |
|
163
Fate Therapeutics
FATE
$281M
| $21.8M | 0.15% |
250,737
-19,370
| -7% | -$1.56M |
|
164
Elevance Health
ELV
$81.9B
| $21.7M | 0.15% |
56,851
-10,821
| -16% | -$4.14M |
|
165
Southern Copper
SCCO
$141B
| $21.4M | 0.15% |
358,888
+263,961
| +278% | +$17.2M |
|
|
IPG
166
DELISTED
Interpublic Group of Companies
IPG
| $21.3M | 0.15% |
656,238
+418,638
| +176% | +$13.4M |
|
167
Broadcom
AVGO
$1.82T
| $21.3M | 0.15% |
446,770
-688,540
| -61% | -$31.9M |
|
168
Morgan Stanley
MS
$337B
| $21.1M | 0.14% |
222,431
-222,749
| -50% | -$19.1M |
|
169
Colgate-Palmolive
CL
$72.6B
| $21.1M | 0.14% |
259,143
+126,326
| +95% | +$10.3M |
|
170
Ambarella
AMBA
$2.99B
| $21M | 0.14% |
197,248
-55,014
| -22% | -$5.45M |
|
171
PNC Financial Services
PNC
$100B
| $20.7M | 0.14% |
108,608
+5,150
| +5% | +$967K |
|
172
Relay Therapeutics
RLAY
$4.02B
| $20.6M | 0.14% |
562,938
+562,927
| +5,117,518% | +$18.6M |
|
|
Y
173
DELISTED
Alleghany Corp
Y
| $20.2M | 0.14% |
+25,082
| New | +$17.3M |
|
|
APLS
174
DELISTED
Apellis Pharmaceuticals
APLS
| $20.1M | 0.14% |
317,315
-238,059
| -43% | -$12.3M |
|
175
Curis
CRIS
$9.53M
| $20M | 0.14% |
+6,200
| New | +$28M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2021 Portfolio in Review
As of Q2 2021, Candriam SCA held 958 positions worth $14.6B, up 22% from $12B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $859M of net new capital in Q2 2021, opening 131 new positions and adding to 364 existing holdings. Its largest new stake was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 34% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $90.3M trimmed.
- Candriam SCA's largest Q2 2021 buy was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
- Candriam SCA added most to Microsoft in Q2 2021, an estimated $135M increase.
- Candriam SCA's biggest Q2 2021 reduction was Bristol-Myers Squibb, cutting an estimated $90.3M.
- Candriam SCA fully exited Tenable Holdings in Q2 2021, selling an estimated $31.6M.
- Candriam SCA's ten largest holdings make up 22% of its $14.6B portfolio in Q2 2021.
- Candriam SCA opened 131 new positions and closed 74 in Q2 2021.
- Candriam SCA's portfolio value rose 22% quarter-over-quarter to $14.6B.
Based on Candriam SCA's 13F filing for Q2 2021, filed 20 Jul 2021.